Kemp Dolliver
Stock Analyst at Brookline Capital
(0.47)
# 4,153
Out of 5,056 analysts
16
Total ratings
33.33%
Success rate
-20.39%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.22 | - | 1 | Aug 19, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $4.30 | +318.60% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.05 | +1,460.98% | 1 | Jul 15, 2025 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $3.83 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $1.21 | +197.52% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $1.78 | +1,922.47% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.91 | +1,543.98% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $53.50 | +86.92% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $1.74 | +3,175.86% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $5.06 | +394.07% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.05 | +271.29% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.58 | +1,279.79% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.72 | +681.68% | 1 | Feb 2, 2022 |
Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.22
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.30
Upside: +318.60%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.05
Upside: +1,460.98%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.83
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $1.21
Upside: +197.52%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.78
Upside: +1,922.47%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.91
Upside: +1,543.98%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $53.50
Upside: +86.92%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.74
Upside: +3,175.86%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $5.06
Upside: +394.07%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $5.05
Upside: +271.29%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.58
Upside: +1,279.79%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.72
Upside: +681.68%